ERBB2 and acute lymphoblastic leukemia: The patient cohort comprised 25 women (38%) and 40 men (62%) with no significant difference between the 2 groups (4 women (24%) and 13 men (76%) vs. 21 women (44%) and 27 men (56%) with HER2/neu+ and HER2/neu− ALL, respectively; p = 0.14).